Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNS NASDAQ:ASNS NASDAQ:CGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNSActelis Networks$0.62+19.8%$0.48$0.33▼$1.78$6.46M1.8623.09 million shs2.08 million shsASNSActelis Networks$0.62+19.8%$0.48$0.33▼$1.78$6.46M1.8623.09 million shs2.08 million shsCGTXCognition Therapeutics$1.80-1.6%$1.79$0.22▼$3.83$134.55M1.193.13 million shs1.61 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNSActelis Networks0.00%-17.54%+18.25%-14.15%+51,509,900.00%ASNSActelis Networks0.00%-17.54%+18.25%-14.15%+51,509,900.00%CGTXCognition Therapeutics0.00%+18.06%-15.67%+202.48%+357.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNSActelis Networks$0.62+19.8%$0.48$0.33▼$1.78$6.46M1.8623.09 million shs2.08 million shsASNSActelis Networks$0.62+19.8%$0.48$0.33▼$1.78$6.46M1.8623.09 million shs2.08 million shsCGTXCognition Therapeutics$1.80-1.6%$1.79$0.22▼$3.83$134.55M1.193.13 million shs1.61 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNSActelis Networks0.00%-17.54%+18.25%-14.15%+51,509,900.00%ASNSActelis Networks0.00%-17.54%+18.25%-14.15%+51,509,900.00%CGTXCognition Therapeutics0.00%+18.06%-15.67%+202.48%+357.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNSActelis Networks 2.00Hold$5.00709.98% UpsideASNSActelis Networks 2.00Hold$5.00709.98% UpsideCGTXCognition Therapeutics 2.80Moderate Buy$2.8357.41% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, ASNS, and ASNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ASNSActelis NetworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ASNSActelis NetworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ASNSActelis NetworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ASNSActelis NetworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CGTXCognition TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNSActelis Networks$7.76M1.00N/AN/A$0.36 per share1.71ASNSActelis Networks$7.76M1.00N/AN/A$0.36 per share1.71CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNSActelis Networks-$4.37M-$0.780.00N/AN/A-115.31%-264.19%-80.77%11/13/2025 (Estimated)ASNSActelis Networks-$4.37M-$0.780.00N/AN/A-115.31%-264.19%-80.77%11/13/2025 (Estimated)CGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)Latest CGTX, ASNS, and ASNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ASNSActelis Networks-$0.16-$0.21-$0.05-$0.21$1.00 million$0.94 million8/14/2025Q2 2025ASNSActelis Networks-$0.16-$0.21-$0.05-$0.21$1.00 million$0.94 million8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNSActelis NetworksN/AN/AN/AN/AN/AASNSActelis NetworksN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNSActelis Networks0.151.140.54ASNSActelis Networks0.151.140.54CGTXCognition TherapeuticsN/A1.541.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNSActelis Networks12.43%ASNSActelis Networks12.43%CGTXCognition Therapeutics43.35%Insider OwnershipCompanyInsider OwnershipASNSActelis Networks1.66%ASNSActelis Networks1.66%CGTXCognition Therapeutics14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNSActelis Networks4012.55 million12.34 millionN/AASNSActelis Networks4012.55 million12.34 millionN/ACGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableCGTX, ASNS, and ASNS HeadlinesRecent News About These CompaniesCognition Therapeutics' (CGTX) "Sell (E+)" Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comCognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the UpgradeOctober 8, 2025 | zacks.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $2.83 Consensus PT from AnalystsOctober 8, 2025 | americanbankingnews.comCognition Therapeutics (NASDAQ:CGTX) Stock Price Up 13.6% - Still a Buy?October 8, 2025 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesOctober 3, 2025 | marketbeat.comCognition Therapeutics (NASDAQ:CGTX) Downgraded to Sell Rating by Wall Street ZenSeptember 26, 2025 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest UpdateSeptember 17, 2025 | marketbeat.comThese Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025September 3, 2025 | msn.comCognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollmentSeptember 3, 2025 | msn.comCognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support ...September 3, 2025 | markets.businessinsider.comCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment TargetSeptember 3, 2025 | markets.businessinsider.comCognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease TreatmentSeptember 3, 2025 | quiverquant.comQCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment TargetSeptember 3, 2025 | globenewswire.comCognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)September 2, 2025 | globenewswire.comCognition Therapeutics stock falls after $30 million direct offeringAugust 28, 2025 | in.investing.comCognition Therapeutics launches $30M share offeringAugust 28, 2025 | msn.comCognition Therapeutics, Inc. Announces $30 Million Registered Direct Offering to Fund Phase 3 Programs for Neurodegenerative DisordersAugust 27, 2025 | quiverquant.comQCognition Therapeutics Announces $30 Million Registered Direct Offering of Common StockAugust 27, 2025 | globenewswire.comCognition Therapeutics Regains Nasdaq ComplianceAugust 27, 2025 | msn.comCognition Therapeutics regains compliance with NasdaqAugust 26, 2025 | msn.comCognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" RatingAugust 26, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, ASNS, and ASNS Company DescriptionsActelis Networks NASDAQ:ASNS$0.62 +0.10 (+19.84%) Closing price 04:00 PM EasternExtended Trading$0.61 0.00 (-0.70%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.Actelis Networks NASDAQ:ASNS$0.62 +0.10 (+19.84%) Closing price 04:00 PM EasternExtended Trading$0.61 0.00 (-0.70%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.Cognition Therapeutics NASDAQ:CGTX$1.80 -0.03 (-1.64%) Closing price 04:00 PM EasternExtended Trading$1.79 -0.01 (-0.56%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
